These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29893681)

  • 21. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
    Ma W; Guo X; Wang Q; Sun G; Wang J
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):32-41. PubMed ID: 32251022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel treatment strategy of new onset atrial fibrillation after cardiac surgery: an observational prospective study.
    Zeriouh M; Sabashnikov A; Choi YH; Fatullayev J; Reuter H; Popov AF; Langebartels G; Kimmig L; Rahmanian PB; Wittwer T; Neef K; Wippermann J; Wahlers T
    J Cardiothorac Surg; 2014 May; 9():83. PubMed ID: 24886207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D; Pratt CM; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Nielsen T; Rasmussen SL; Stiell IG; Coutu B; Ip JH; Pritchett EL; Camm AJ;
    Circulation; 2008 Mar; 117(12):1518-25. PubMed ID: 18332267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M
    Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.
    Simon A; Niederdoeckl J; Skyllouriotis E; Schuetz N; Herkner H; Weiser C; Laggner AN; Domanovits H; Spiel AO
    Europace; 2017 Feb; 19(2):233-240. PubMed ID: 28175295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
    Camm AJ; Toft E; Torp-Pedersen C; Vijayaraman P; Juul-Moller S; Ip J; Beatch GN; Dickinson G; Wyse DG;
    Europace; 2012 Jun; 14(6):804-9. PubMed ID: 22291438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
    Guerra F; Matassini MV; Scappini L; Urbinati A; Capucci A
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1067-75. PubMed ID: 25096598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation.
    Conde D; Costabel JP; Aragon M; Lambardi F; Klein A; Corrales Barbosa A; Trivi M; Giniger A
    Cardiovasc Ther; 2013 Dec; 31(6):377-80. PubMed ID: 23683253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
    Akel T; Lafferty J
    Ann Noninvasive Electrocardiol; 2018 May; 23(3):e12508. PubMed ID: 29105209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN; Eschenhagen T
    Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation.
    Conde D; Costabel JP; Caro M; Ferro A; Lambardi F; Corrales Barboza A; Lavalle Cobo A; Trivi M
    Int J Cardiol; 2013 Oct; 168(3):2423-5. PubMed ID: 23518212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.
    Fedida D
    Expert Opin Investig Drugs; 2007 Apr; 16(4):519-32. PubMed ID: 17371199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D
    Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion.
    Müssigbrodt A; John S; Kosiuk J; Richter S; Hindricks G; Bollmann A
    Europace; 2016 Jan; 18(1):51-6. PubMed ID: 26056189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
    Blomström-Lundqvist C; Blomström P
    Expert Opin Drug Saf; 2012 Jul; 11(4):671-9. PubMed ID: 22632377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.